All Stories

  1. Deciphering the Cellular Behavior of Organoruthenium(II)-Pyrithionato Complexes in Ovarian Cancers
  2. Polynuclear Silver(I)–Quinoxaline Complex: Comprehensive Structural Characterization, Antimycobacterial Properties and DNA/BSA Binding Study
  3. Structure and solution biospeciation on tricarbonylrhenium(I) complexes of mercaptopyrimidines with multifaceted biological activity
  4. Silver(I) complexes with antifungal drug econazole: Structural characterization and antimicrobial activity study
  5. Dinuclear Gallium(III) Complex With 1,3‐Propanediamine‐N,N′‐Diacetate: Structural Characterization, Antimicrobial Activity, and DNA/BSA Interactions
  6. Silver(i) complexes containing antifungal azoles: significant improvement of the anti-Candida potential of the azole drug after its coordination to the silver(i) ion
  7. Organometallic Ru(ii), Rh(iii) and Re(i) complexes of sterane-based bidentate ligands: synthesis, solution speciation, interaction with biomolecules and anticancer activity
  8. Synergy of experimental and computational chemistry: structure and biological activity of Zn(ii) hydrazone complexes
  9. Nickel(II) and nickel(III) thiosemicarbazone and hydrazone complexes: An unexpected journey
  10. Reactions of Medicinal Gold Compounds with Cathepsin B Explored through Electrospray Mass Spectrometry Measurements
  11. Correlating Structure and KA2 Catalytic Activity of ZnII Hydrazone Complexes
  12. Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds
  13. Novel Organoruthenium(II) Complex C1 Selectively Inhibits Butyrylcholinesterase without Side Effects on Neuromuscular Transmission
  14. Copper(ii) and silver(i) complexes with dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz): the influence of the metal ion on the antimicrobial potential of the complex
  15. Silver(I) Complexes with Clinically Used Azoles: Synthesis, Structural Characterization and Antimicrobial Evaluation
  16. Coordination preferences of NNO and NNS Schiff base ligands with Co(III) complexes: Synthesis, characterization and DFT calculation
  17. Nanosecond electric pulses are equally effective in electrochemotherapy with cisplatin as microsecond pulses
  18. Kinetic Characterization of Cerium and Gallium Ions as Inhibitors of Cysteine Cathepsins L, K, and S
  19. Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line
  20. Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
  21. Zinc(II) Complexes with Dimethyl 2,2′-Bipyridine-4,5-dicarboxylate: Structure, Antimicrobial Activity and DNA/BSA Binding Study
  22. Metal(II) Complexes of the Fluoroquinolone Fleroxacin: Synthesis, Characterization and Biological Profile
  23. Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
  24. Clinically used antifungal azoles as ligands for gold(iii) complexes: the influence of the Au(iii) ion on the antimicrobial activity of the complex
  25. Cu(ii), Mn(ii) and Zn(ii) complexes of hydrazones with a quaternary ammonium moiety: synthesis, experimental and theoretical characterization and cytotoxic activity
  26. Pyrithione metal (Cu, Ni, Ru) complexes as photo-catalysts for styrene oxide production
  27. Fine Tuning of Cholinesterase and Glutathione-S-Transferase Activities by Organoruthenium(II) Complexes
  28. Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance
  29. Comparison of Solution Chemical Properties and Biological Activity of Ruthenium Complexes of Selected β-Diketone, 8-Hydroxyquinoline and Pyrithione Ligands
  30. Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells
  31. Large enhancement of photocatalytic activity in ZnO thin films grown by plasma-enhanced atomic layer deposition
  32. Structural Characterization, Antimicrobial Activity and BSA/DNA Binding Affinity of New Silver(I) Complexes with Thianthrene and 1,8-Naphthyridine
  33. Structure of Biologically Active Benzoxazoles: Crystallography and DFT Studies
  34. Tailoring copper(ii) complexes with pyridine-4,5-dicarboxylate esters for anti-Candida activity
  35. Copper(II) and Zinc(II) Complexes with the Clinically Used Fluconazole: Comparison of Antifungal Activity and Therapeutic Potential
  36. Synthesis, X-ray structures and magnetic properties of Ni(II) complexes of heteroaromatic hydrazone
  37. Synthesis, structural determination, in vitro and in silico biological evaluation of divalent or trivalent cobalt complexes with indomethacin
  38. Synthesis, Characterization, Catalytic Activity, and DFT Calculations of Zn(II) Hydrazone Complexes
  39. Cobalt(II), Zinc(II), Iron(III), and Copper(II) Complexes Bearing Positively Charged Quaternary Ammonium Functionalities: Synthesis, Characterization, Electrochemical Behavior, and SOD Activity
  40. Structural Isomerism and Enhanced Lipophilicity of Pyrithione Ligands of Organoruthenium(II) Complexes Increase Inhibition on AChE and BuChE
  41. Structural and functional characterization of an organometallic ruthenium complex as a potential myorelaxant drug
  42. Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS
  43. Silver(i) complexes with different pyridine-4,5-dicarboxylate ligands as efficient agents for the control of cow mastitis associated pathogens
  44. Synthesis, X-ray structure and DFT calculation of magnetic properties of binuclear Ni(II) complex with tridentate hydrazone-based ligand
  45. Combined Experimental and Theoretical Investigation of the Origin of Magnetic Anisotropy in Pentagonal Bipyramidal Isothiocyanato Co(II), Ni(II) and Fe(III) Complexes With Quaternary Ammonium-functionalized 2,6-Diacetylpyridine Bisacylhydrazone
  46. Towards Identification of Essential Structural Elements of Organoruthenium(II)‐Pyrithionato Complexes for Anticancer Activity
  47. Covalent versus Noncovalent Binding of Ruthenium η 6 ‐ p ‐Cymene Complexes to Zinc‐Finger Protein NCp7
  48. Organoruthenated Nitroxoline Derivatives Impair Tumor Cell Invasion through Inhibition of Cathepsin B Activity
  49. What Is the Nature of Interactions of BF4–, NO3–, and ClO4– to Cu(II) Complexes with Girard’s T Hydrazine? When Can Binuclear Complexes Be Formed?
  50. Highly-efficient N-arylation of imidazole catalyzed by Cu(II) complexes with quaternary ammonium-functionalized 2-acetylpyridine acylhydrazone
  51. Organometallic ruthenium(II)-arene complexes with triphenylphosphine amino acid bioconjugates: Synthesis, characterization and biological properties
  52. Organoruthenium(II) complexes of acetazolamide potently inhibit human carbonic anhydrase isoforms I, II, IX and XII
  53. Anti-cancer organoruthenium(ii) complexes and their interactions with cysteine and its analogues. A mass-spectrometric study
  54. Comparative antitumor studies of organoruthenium complexes with 8-hydroxyquinolines on 2D and 3D cell models of bone, lung and breast cancer
  55. Synthesis, Biological Evaluation and Docking Studies of Benzoxazoles Derived from Thymoquinone
  56. Synthesis, structures and magnetic properties of octahedral Co(III) complexes of heteroaromatic hydrazones with tetraisothiocyanato Co(II) anions
  57. Organoruthenium Prodrugs as a New Class of Cholinesterase and Glutathione-S-Transferase Inhibitors
  58. Synthesis and biological characterization of organoruthenium complexes with 8-hydroxyquinolines
  59. C-H Bond Activation by a Ruthenium(II) β -Diketonate Complex: A Mechanistic Study
  60. Structural diversity of isothiocyanato Cd(II) and Zn(II) Girard’s T hydrazone complexes in solution and solid state: effect of H-bonding on coordination number and supramolecular assembly of Cd(II) complex in solid state
  61. Crystal structures and DFT calculations of mixed chloride-azide zinc(II) and chloride-isocyanate cadmium(II) complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard's T reagent
  62. Concomitant polymorphism in an organometallic ruthenium(II) complex with an N,N′-donor ligand
  63. Manganese(II) complexes of the quinolone family member flumequine: Structure, antimicrobial activity and affinity for albumins and calf-thymus DNA
  64. Correction to: Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes
  65. Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes
  66. Molecular Structures and Spin-States of Pseudohalide Metal Complexes with Hydrazones of Girard's T Reagent
  67. A new class of platinum(ii) complexes with the phosphine ligand pta which show potent anticancer activity
  68. How zinc ions shift and enhance the nucleotide's fluorescence spectra
  69. Extending the family of quinolone antibacterials to new copper derivatives: self-assembly, structural and topological features, catalytic and biological activity
  70. Crystal structures, magnetic properties and DFT study of cobalt(II) azido complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  71. Synthesis, characterization and antimicrobial activity of isothiocyanato Fe(III) Girard's t hydrazone complex
  72. Synthesis, characterization, DFT calculations and antimicrobial activity of Cd(II) complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  73. Synthesis, crystal structures and antimicrobial activity of azido and isocyanato Zn(II) complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  74. Synthesis, characterization and crystal structures of two pentagonal-bipyramidal Fe(III) complexes with dihydrazone of 2,6-diacetylpyridine and Girard's T reagent. Anticancer properties of various metal complexes of the same ligand
  75. Synthesis, crystal structure, magnetic properties and DFT study of dinuclear Ni(II) complex with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  76. Synthesis and Structural Evaluation of Organo-Ruthenium Complexes with β-Diketonates
  77. β-Diketones as Scaffolds for Anticancer Drug Design - From Organic Building Blocks to Natural Products and Metallodrug Components
  78. Copper(II) complexes with gatifloxacin
  79. Cobalt(II) complexes of sparfloxacin
  80. Synthesis, characterization, DFT calculations and antimicrobial activity of pentagonal-bipyramidal Zn(II) and Cd(II) complexes with 2,6-diacetylpyridine-bis(trimethylammoniumacetohydrazone)
  81. Co-NSAIDs
  82. Interactions of two cytotoxic organoruthenium(II) complexes with G-quadruplex
  83. Interactions of the “piano-stool” [ruthenium(II)(η6-arene)(quinolone)Cl]+complexes with water; DFT computational study
  84. Synthesis, characterization and antimicrobial activity of pentagonal-bipyramidal isothiocyanato Co(II) and Ni(II) complexes with 2,6-diacetylpyridine bis(trimethylammoniumacetohydrazone)
  85. Synthesis and characterization of ML and ML2 metal complexes with amino acid substituted bis(2-picolyl)amine ligands
  86. Pyrithione-based ruthenium complexes as inhibitors of aldo–keto reductase 1C enzymes and anticancer agents
  87. Structure and biological activities of metal complexes of flumequine
  88. Clioquinol–ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity
  89. Investigation of antitumor potential of Ni(II) complexes with tridentate PNO acylhydrazones of 2-(diphenylphosphino)benzaldehyde and monodentate pseudohalides
  90. Ruthenium complexes as inhibitors of 15-lipoxygenase-1
  91. Synthesis, crystal structures, and antimicrobial activity of square-planar chloride and isocyanate Ni(II) complexes with the condensation product of 2-(diphenylphosphino)benzaldehyde and Girard’s T reagent
  92. New synthetic routes for the preparation of ruthenium-1,10-phenanthroline complexes. Tests of cytotoxic and antibacterial activity of selected ruthenium complexes
  93. Ruthenium complexes as inhibitors of the aldo–keto reductases AKR1C1–1C3
  94. Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates
  95. Special Issue: Practical Applications of Metal Complexes
  96. Experimental and theoretical investigation of octahedral and square-planar isothiocyanato complexes of Ni(II) with acylhydrazones of 2-(diphenylphosphino)benzaldehyde
  97. Manganese(II)–sparfloxacinato complexes
  98. Cobalt-oxolinato complexes
  99. New method for the speciation of ruthenium-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks
  100. Synthesis, characterization, DFT calculation and biological activity of square-planar Ni(II) complexes with tridentate PNO ligands and monodentate pseudohalides. Part II
  101. Cobalt(II) complexes of enrofloxacin
  102. Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo
  103. New Water-Soluble Ruthenium(II) Terpyridine Complexes for Anticancer Activity: Synthesis, Characterization, Activation Kinetics, and Interaction with Guanine Derivatives
  104. Synthesis and Biological Evaluation of Organoruthenium Complexes with Azole Antifungal Agents. First Crystal Structure of a Tioconazole Metal Complex
  105. Zinc-tolfenamato
  106. Analysis of the structures of the Cu(I) and Cu(II) complexes with 3-acetylpyridine and thiocyanate
  107. Manganese(II) complexes of tolfenamic acid
  108. Structural characterization and biological evaluation of a clioquinol–ruthenium complex with copper-independent antileukaemic activity
  109. Zinc complexes of mefenamic acid
  110. Synthesis, characterization, DFT calculations and biological activity of derivatives of 3-acetylpyridine and the zinc(II) complex with the condensation product of 3-acetylpyridine and semicarbazide
  111. New Uses for Old Drugs: Attempts to Convert Quinolone Antibacterials into Potential Anticancer Agents Containing Ruthenium
  112. Manganese(II) complexes of niflumic acid
  113. Zinc complexes of oxolinic acid, flumequine, enrofloxacin
  114. Novel Organoruthenium(II) β-Diketonates as Catalysts for Ortho Arylation via C–H Activation
  115. Zinc complexes of flumequine
  116. Copper complexes with ofloxacin and norfloxacin - synthesis, structure na bioactivity
  117. Copper(II) complexes of flumequine
  118. Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex
  119. Cobalt(II)-tolfenamato complexes
  120. Factors that influence the antiproliferative activity of half sandwich RuII–[9]aneS3 coordination compounds: activation kinetics and interaction with guanine derivatives
  121. Copper - diflunisal
  122. Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
  123. Nickel–quinolones-bipyam complexes
  124. Synthesis, characterization, cytotoxic activity and DNA binding properties of the novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide
  125. Physicochemical Studies and Anticancer Potency of Ruthenium η6-p-Cymene Complexes Containing Antibacterial Quinolones
  126. Copper(II) complexes of naproxen / diclofenac
  127. 1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity
  128. Zinc complexes of sparfoxacin - levofloxacin
  129. First Ruthenium Organometallic Complex of Antibacterial Agent Ofloxacin. Crystal Structure and Interactions with DNA
  130. Pyridyl Conjugated 1,2,3-Triazole is a Versatile Coordination Ability Ligand Enabling Supramolecular Associations
  131. Di-μ-chlorido-bis{chlorido[(R)/(S)-1,5-diphenyl-3-(2-pyridyl-κN)-2-pyrazoline-κN2]zinc(II)}
  132. Nickel complexes of flumequine
  133. Intermolecular C—H...π interactions in 1,5-diphenyl-3-(2-pyridyl)-2-pyrazoline
  134. Click-Triazole N2 Coordination to Transition-Metal Ions Is Assisted by a Pendant Pyridine Substituent
  135. Strong Correlations in Highly Electron-Doped Zn(II)-DNA Complexes
  136. Nickel complexes of oxolinic acid
  137. Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine
  138. Magnesium complexes of ciprofloxacin
  139. Spectral properties of Eu(III) compound with antibacterial agent ciprofloxacin (cfqH). Crystal structure of [Eu(cfqH)(cfq)(H2O)4]Cl2·4.55H2O
  140. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro
  141. Erratum to: Synthesis, characterization and DNA binding of magnesium-ciprofloxacin (cfH) complex [Mg(cf)2] · 2.5H2O [J. Inorg. Biochem. 100 (2006) 1705–1713]
  142. Optical spectra of wet and dry M -DNA
  143. Experimental electron density study of a complex between copper(ii) and the antibacterial quinolone family member ciprofloxacin
  144. X-Ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fluoroquinolones – racemic ofloxacin and its S-form, levofloxacin
  145. catena-Poly[[[tetrakis(μ-acetato-κ2O:O′)dirhodium(II)]-μ-[1,3-bis(dimethylamino)propan-2-ol-κ2N:N′]] tetrahydrofuran hemisolvate]
  146. Synthesis, characterization and DNA binding of magnesium–ciprofloxacin (cfH) complex [Mg(cf)2] · 2.5H2O
  147. Ruthenium complexes with purine derivatives: Syntheses, structural characterization and preliminary studies with plasmidic DNA
  148. Mixed-valence Cu(II)/Cu(I) complex of quinolone ciprofloxacin isolated by a hydrothermal reaction in the presence of l-histidine: comparison of biological activities of various copper–ciprofloxacin compounds
  149. Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives
  150. A novel copper(II) complex with 1,10-phenanthroline and ciprofloxacin
  151. Influence of copper(II) and magnesium(II) ions on the ciprofloxacin binding to DNA
  152. Ruthenium(III)-DMSO complexes of the antiherpes drug acyclovir
  153. Characterization of ciprofloxacin binding to the linear single- and double-stranded DNA
  154. Interactions of oxovanadium(IV) and the quinolone family member—ciprofloxacin
  155. Crystal Structure of Ciprofloxacin Hydrochloride 1.34-Hydrate.
  156. Interaction between ciprofloxacin and DNA mediated by Mg2+-ions
  157. The interactions of metal ions with quinolone antibacterial agents
  158. Novel RuIII-DMSO Complexes of the Antiherpes Drug Acyclovir
  159. Erratum to In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds
  160. In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds
  161. Biological Activity of Some Magnesium(II) Complexes of Quinolones
  162. Complexes of copper (II) acetate with nicotinamide: preparation, characterization and fungicidal activity; crystal structures of [Cu2 (O2CCH3)4 (nia)] and [Cu2 (O2CCH3)4 (nia)2]
  163. NMR Investigation of the Copper(II)‐Ciprofloxacin System
  164. New studies in the copper(II) acyclovir (acv) system. NMR relaxation studies and the X-ray crystal structure of [Cu(acv)2(H2O)2](NO3)2
  165. Antibacterial tests of Bismuth(III)–Quinolone (Ciprofloxacin, cf) compounds against Helicobacter pylori and some other bacteria. Crystal structure of (cfH2)2[Bi2Cl10]·4H2O
  166. Complexes of copper(II) carboxylates with 2-aminoethanol - syntheses, characterization and fungicidal activity; crystal structure of Cu(O2CC8H17)2(NH2C2H4OH)2
  167. Effect of Copper Acyclovir Complexes on Herpes Simplex Virus Type 1 and Type 2 (HSV-1, HSV-2) Infection in Cultured Cells
  168. Boron Complex of a Member of the Quinolone Family
  169. Crystal structure of ciprofloxacin hexahydrate and its characterization
  170. Crystal structure and characterization of the bismuth(III) compound with quinolone family member (ciprofloxacin). Antibacterial study
  171. Synthesis, crystal structure, and characterization of two metal-quinolone compounds
  172. Synthesis and characterization of copper(II) coordination compounds with acyclovir: crystal structure of triaquabis [9-{(2-hydroxyethoxy)methyl>guanine] copper(II) nitrate (V) hydrate
  173. An Adduct of Magnesium Sulfate with a Member of the Quinolone Family (Ciprofloxacin)
  174. Comparison of the thermal stability of ciprofloxacin and its compounds
  175. The crystal structure and characterization of a copper(II) complex with a guanosine-5′-monophosphate analog (acyclovir monophosphate)
  176. Synthesis, crystal structure, and characterization of three novel compounds of the quinolone family member (norfloxacin)
  177. Complex formation between some metals and a quinolone family member (ciprofloxacin)
  178. Synthesis, characterization, and crystal structure of a copper(II) complex with quinolone family member (ciprofloxacin): bis(1)-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1ylquinoline-3-carboxylate) copper(II) chloride hexahydrate
  179. Synthesis and structure of diaquadichlorobis {9-[(2-hydroxyethoxy)methyl]guanine} copper(II)